
Loading, please wait...

Loading, please wait...

Management of muscle-invasive urothelial carcinoma (MIUC) is entering a new era. For years, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has remained the gold standard. However, many patients cannot undergo this regimen due to renal dysfunction or significant comorbidities. Neoadjuvant immune checkpoint inhibitors (ICIs) are now emerging as a transformative alternative for these individuals. This systematic review evaluates the efficacy and safety of ICIs in the preoperative setting.
The meta-analysis demonstrates that neoadjuvant immune checkpoint inhibitors significantly improve clinical outcomes. Specifically, these agents achieve a pathological complete response (pCR) in approximately 31% to 37% of patients. This response rate is highly encouraging, especially for those ineligible for traditional chemotherapy. Furthermore, ICIs show a favorable safety profile compared to molecular targeted agents. Grade 3 or higher adverse events occur in roughly 35% of cases. Consequently, surgeons can proceed with radical cystectomy without significant delays. Notably, high PD-L1 expression often correlates with better response rates. Therefore, clinicians might use biomarkers to select the best candidates for this therapy in the future.
Moreover, trials like PURE-01 and ABACUS have paved the way for these findings. These studies show that pembrolizumab and atezolizumab can downstage tumors effectively. Additionally, the meta-analysis confirms that ICI monotherapy performs better than targeted agents in terms of pCR and downstaging. Doctors must consider these findings when planning surgery for MIUC patients. This approach not only targets the primary tumor but also addresses potential micrometastatic disease.
Currently, clinical guidelines primarily recommend neoadjuvant immune checkpoint inhibitors for patients who are ineligible for cisplatin. Cisplatin-based chemotherapy remains the standard for fit patients, although ongoing trials are exploring combination therapies.
Recent meta-analyses indicate that ICI monotherapy achieves a pCR rate between 31% and 37%. When oncology teams combine these with chemotherapy, these rates may increase significantly.
Evidence suggests that most patients tolerate ICIs well enough to undergo radical cystectomy on schedule. Serious adverse events occur in about 35% of patients, but surgical delays remain relatively rare.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A meta-analysis examines neoadjuvant immune checkpoint inhibitors as a viable treatment path for cisplatin-ineligible muscle-invasive urothelial carcinoma....
7 months ago

A prospective multicenter cohort study demonstrates that baseline health-related quality of life, particularly physical functioning, independently predicts all-cause maintenance hemodialysis mortality. Assessing patient-reported outcomes provides vital prognostic value beyond standard biochemical markers.
Today

Delhi is undergoing a major healthcare overhaul with enhanced Ayushman Bharat insurance up to ₹10 lakh, increased MBBS and PG medical training seats, expanded primary network mandirs, new tertiary neuro-ICUs, and public-private reproductive technology initiatives to build a resilient, preventative healthcare model.
Today

Aon forecasts India's healthcare inflation will ease to 10.1% in 2027 from 11.5% in 2026. Despite moderation, healthcare expenses continue to outpace general inflation, propelled by non-communicable diseases, advanced medical therapeutics, and expanding utilization patterns across diverse patient populations.
Today

Non-union fractures occur in 2-5% of cases, causing significant disability and cost. Conservative modalities such as LIPUS, PEMF, and focused ESWT offer non-surgical healing options for defects up to 5-10 mm when adequate mechanical stability exists without infection.
Today

Explore how novel oxygen-releasing PVA hydrogels prevent early post-transplant hypoxic damage in pancreatic beta cells, sustaining viability and insulin secretory function.
Today